Artal Group S.A. Replimune Group, Inc. Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$17.48 - $29.09 $3.5 Million - $5.82 Million	-200,000 Reduced 28.57%	500,000 $8.83 Million
Q4 2022 Feb 13, 2023	SELL	$17.09 - $27.91 $3.42 Million - $5.58 Million	-200,000 Reduced 22.22%	700,000 $19 Million
Q2 2021 Aug 13, 2021	BUY	$28.5 - $39.37 $2.85 Million - $3.94 Million	100,000 Added 12.5%	900,000 $34.6 Million
Q1 2021 May 14, 2021	BUY	$30.22 - $45.57 $3.02 Million - $4.56 Million	100,000 Added 14.29%	800,000 $24.4 Million
Q3 2020 Nov 13, 2020	SELL	$18.85 - $27.0 $942,500 - $1.35 Million	-50,000 Reduced 6.67%	700,000 $16.1 Million
Q2 2020 Aug 14, 2020	BUY	$9.76 - $25.95 $1.46 Million - $3.89 Million	150,000 Added 25.0%	750,000 $18.6 Million
Q1 2019 May 10, 2019	BUY	$10.26 - $16.24 $1.54 Million - $2.44 Million	150,000 Added 33.33%	600,000 $9.13 Million
Q3 2018 Nov 09, 2018	BUY	$14.99 - $22.14 $6.75 Million - $9.96 Million	450,000 New	450,000 $7.25 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $693M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.